Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Chang-Yuan Hsu,Che-Wei Chang,Su-Boon Yong,Chin-Yuan Yii

doi:10.1016/j.phrs.2025.107639

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Chang-Yuan Hsu, Che-Wei Chang + Show 2 more

https://doi.org/10.1016/j.phrs.2025.107639

Copy DOI

Export

Save

Cite

Journal: Pharmacological research

Publication Date: Feb 1, 2025

#High Cardiovascular Risk #Real-world Setting #Weight Control #Diabetic Patients #Glycemic Control #High Risk #SGLT2 Inhibitor #Obese Type #Cardiovascular Risk

Abstract
Full-Text
Similar Papers

Abstract

Listen

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Pharmacological research

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.